Role of HER-2/neu overexpression and clinical features at presentation as predictive factors in meningiomas

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 5, 2004, Pages 452-456

  Potti, Anil ^a   Panwalkar, Amit ^b   Langness, Eric ^b   Sholes, Kaley ^b   Tendulkar, Ketki ^b   Chittajalu, Siddarth ^b   Koch, Michael ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UND School of Medicine & Health Sciences Southeast Campus   (United States)

Author keywords

Her 2 neu overexpression; Meningioma; Predictive factors; Symptoms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN BIOPSY; CANCER INCIDENCE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; ONCOGENE NEU; PROGNOSIS; SCORING SYSTEM; SEIZURE; SEX RATIO; SYNCOPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SYNCOPE;

EID: 5644291956     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000128724.63600.c7     Document Type: Article

References (37)

1. Chozick BS, Benzil DL, Stopa EG, et al. Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas. J Neurooncol. 1996;27:117-126.
2. Staneczek W, Janisch W. Epidemiologic data on meningiomas in East Germany 1961-1986: incidence, localization, age and sex distribution. Clin Neuropathol. 1992;11:135.
3. Radhakrishnan D, Mokri B, Parisi JE, et al. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol. 1995;37:67.
4. Annegers JF, Schoenberg BS, Okazaki H, et al. Epidemiologic study of primary intracranial neoplasms. Arch Neurol. 1981;38:217.
5. Nakasu S, Hirano A, Shimura T, et al. Incidental meningiomas in autopsy study. Surg Neurol. 1987;27:319.
6. Chozick BS, Reinert SE, Greenblatt SH. Incidence of seizures after surgery for supratentorial meningiomas: a modern analysis. J Neurosurg. 1996;84:382.
7. Yamasaki F, Yoshioka H, Hama S, et al. Recurrence of meningiomas. Cancer. 2000;89:1102-1110.
8. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol. 1999;26(suppl 12):51-59.
9. Schneider PM, Hung MC, Chiocca SM, et al. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res. 1989;49:4968-4971.
10. Weiner DB, Nordberg J, Robinson R, et al. Expression of neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res. 1990;50:421-425.
11. Zhang X, Silva E, Greshenson D, et al. Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. Oncogene. 1989;4:985-989.
12. Yokota J, Yamamoto T, Miyajima N, et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene. 1988;2:283-287.
13. Riben MW, Malfetano JH, Nazeer T, et al. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage 1 endometrial carcinoma. Mod Pathol. 1997;10:823-831.
14. Costa MJ, Walls J. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed Mullerian tumors). Clinicopathologic study of 82 cases. Cancer. 1996;77:535-542.
15. Dugan MC, Dergham ST, Kucway R, et al. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas. 1997;14:229-236.
16. Kapitanovic S, Radosevic S, Kapitanovic M, et al. The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997;112:1103-1113.
17. Costa MJ, Walls J, Trelford JD. C-erbB-2 oncoprotein over-expression in uterine cervix carcinoma with glandular differentiation. A frequent event, but not an independent prognostic marker because it occurs late in the disease. Am J Clin Pathol. 1995;104:634-642.
18. Mellemgaard A, Geisler CH, Storm HH. Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemias. Eur J Haematol. 1994;53:218-222.
19. Jimenez RE, Wallis T, Tabasczka P, et al. Determination of HER-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2000;13:37-45.
20. Bluehler H, Bangemann N, Evers K, et al. Effective HER-2/neu diagnosis in breast cancer by a combination of immunochemistry and FISH [abstract]. Proc Am Soc Clin Oncol. 2000;19:76a.
21. Mass RD, Sanders C, Charlene K, et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials [abstract]. Proc Am Soc Clin Oncol. 2000;19:75a.
22. Eustacchio S, Trummer M, Fuchs I, et al. Preservation of cranial nerve function following gamma knife radiosurgery for benign skull base meningiomas: experience in 121 patients with follow-up for 5 to 9. 8 years. Acta Neurochir Suppl. 2002;84:71-76.
23. Stafford SL, Perry A, Suman VJ, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc. 1998;73:936-42.
24. Torp SH, Lindboe CF, Granli US, et al. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas. Clin Neuropathol 2001;20:190-195.
25. Sporn MB, Todaro GJ. Autocrine growth factors and cancer. Nature. 1985;313:747-751.
26. Carroll RS, Black PM, Zhang J, et al. Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg. 1997; 87:315.
27. Shamah SM, Alberta JA, Giannobile WV, et al. Detection of activated platelet-derived growth factor receptors in human meningioma. Cancer Res. 1997;57:4141.
28. Antoniades HN, Galanopoulos T, Neville-Golden J, et al. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer. 1992;50:215.
29. Nishikawa R, Cheng SY, Nagashima R, et al. Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol (Berl). 1998;96:453.
30. Torp SH, Helseth E, Unsgaard G, et al. C-erbB-2/HER-2 protein in human intracranial tumors. Eur J Cancer. 1993;29A:1604-1606.
31. Schwechheimer K, Laufle RM, Schmahl W, et al. Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol. 1994;25:772-780.
32. Custer BS, Koepsell TD, Mueller BA. The association between breast carcinoma and meningioma in women. Cancer. 2002;94:1626-1635.
33. Berchuck A, Kamel A, Whitaker R, et al. Over-expression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50:4087-4091.
34. Gusterson BA, Gelber RD, Goldrisch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10:1049-1056.
35. Schlegel J, Ullrich B, Stumm G, et al. Expression of the c-erbB-2-encoded oncoprotein and progesterone receptor in human meningiomas. Acta Neuropathol (Berl). 1993;86:473-479.
36. Tuzi NL, Venter DJ, Kumar S, et al. Expression of growth factor receptors in human brain tumors. Br J Cancer. 1991;63:227-233.
37. Helseth E, Unsgaard G, Dalen A, et al. Amplification of the epidermal growth factor receptor gene in biopsy specimens from human intracranial tumors. Br J Neurosurg. 1988;2:217-225.